A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Inclusion Criteria

• •1. Height assessment corresponding to a height Z-score of ≤ -2.25 SDs in reference to the general population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth charts
• •2. Tanner Stage 1, at time of signing the ICF (unless too young to stage).
• •Key Exclusions:
• •1. Known chromosomal imbalance or genetic variant causing short stature syndrome, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, Turner syndrome, disproportionate skeletal dysplasias, abnormal SHOX gene analysis, or Rasopathy (including Noonan syndrome)
• •2. Previous treatment with a growth promoting agent